IQ-AI Limited

Equities

IQAI

JE00BD4H0R42

Healthcare Facilities & Services

Market Closed - London S.E. Other stock markets 11:35:26 2024-04-29 am EDT			5-day change	1st Jan Change
1.6 ^GBX	0.00%		+6.67%	-65.96%

Apr. 29	IQ-AI Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 26	IQ-AI's Broker Exercises Option to Buy Shares in Placing	MT

IQ-AI celebrates USD100,000 grant for subsidiary

February 02, 2024 at 03:58 am EST

IQ-AI Ltd - St Helier, Jersey-based medical services firm - Says that Imaging Biometrics LLC, a wholly-owned subsidiary of IQ-AI, has been given a USD100,000 grant by the Musella Foundation For Brain Tumor Research & Information Inc. Explains that the grant will help to support the launch of an intermediate group expanded access programme, which is focused on giving brain tumour patients access to oral gallium maltolate, outside of an ongoing Phase One clinical trial at the Medical College of Wisconsin. The grant will be used to facilitate the expanded access programme, including writing and submitting the study protocol, patient screening and on-boarding.

Current stock price: 3.30 pence, up 4.8% on Friday morning in London

12-month change: up 14%

By Holly Beveridge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about IQ-AI Limited

IQ-AI Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
IQ-AI's Broker Exercises Option to Buy Shares in Placing	Feb. 26	MT
IQ-AI Plans Share Placing to Advance Oral Anti-tumor Agent Development	Feb. 22	MT
IQ-AI shares sink on discounted placing fundraise	Feb. 22	AN
IQ-AI Unit to Revise, Resubmit Pediatric Rare Disease Designation Application After US FDA Feedback	Feb. 09	MT
IQ-AI subsidiary asked by FDA to resubmit and modify application	Feb. 09	AN
IQ-AI Unit Secures Grant for Brain Tumor Pill Access Program	Feb. 02	MT
IQ-AI celebrates USD100,000 grant for subsidiary	Feb. 02	AN
IQ-AI falls after subsidiary notes launch of treatment access scheme	Jan. 10	AN
IQ-AI's Imaging Biometrics Plans Expanded Access Program for Brain Tumor Treatment	Jan. 10	MT
IQ-AI Subsidiary’s Glioblastoma Therapy Obtains Fast-Track Designation From US FDA	Dec. 19	MT
IQ-AI firm gets US FDA fast-track status for oral gallium maltolate	Dec. 19	AN
IQ-AI's Imaging Biometrics Discloses Positive Results in Early-stage Study of Potential Brain Cancer Treatment	Dec. 05	MT
IQ-AI stock rises on positive interim results from glioblastoma trial	Dec. 05	AN
IQ-AI Unit Seeks Pediatric Rare Disease Designation for Brain Tumor Treatment	Nov. 08	MT
IQ-AI says Imaging Biometrics submits paediatric rare disease request	Nov. 08	AN
IQ-AI Applies for FDA Pediatric Rare Disease Designation	Nov. 08	CI
IQ-AI subsidiary "central" to "landmark" brain cancer study	23-10-18	AN
IQ-AI subsidiary wins orphan drug designation from US FDA	23-10-09	AN
IQ-AI's Atypical Teratoid Rhabdoid Tumor Treatment Gains US FDA Orphan Drug Designation	23-10-09	MT
IQ-AI Halts Trading on OTCQB Venture Market in US; London Shares Up 13%	23-09-19	MT
IQ-AI Unit’s Study Validates IB Neuro Platform for Reduced Gadolinium Approach on 1.5T MR Scanners	23-09-08	MT
IQ-AI notes vindication of subsidiary's reduced gadolinium approach	23-09-08	AN
Mayo Clinic Reverts IQ-AI Shares as IB Trax Deal Closes	23-08-18	MT
IQ-AI Shares Up 18% as Unit Strikes Commercial Deal with GE HealthCare	23-08-18	MT

Chart IQ-AI Limited

Duration

Period

More charts

Company Profile

IQ-AI Limited is a Jersey-based company, which is engaged in the provision of clinical treatments to patients in the field of medical imaging diagnostics, based on technology. The Company operates through two segments: holding company expenses and medical software. Its subsidiaries include Imaging Biometrics, LLC and Stone Checker Software Limited. Imaging Biometrics, LLC is a healthcare imaging software company. In addition to providing regulatory consulting services, Imaging Biometrics, LLC supplies medical technology solutions and has a neuroimaging product portfolio. Stone Checker Software Limited is a supplier of technology solutions in the field of kidney stone analysis and kidney stone prevention.

Sector

Healthcare Facilities & Services

Calendar

2024-04-29 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
IQ-AI LIMITED	-65.96%	4.42M
SONIC HEALTHCARE LIMITED	-16.71%	8.25B
RADNET, INC.	+40.93%	3.58B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-35.59%	2.46B
SYNLAB AG	-7.88%	2.46B
DR. LAL PATHLABS LIMITED	-8.95%	2.38B
NEOGENOMICS, INC.	-5.93%	1.81B
FLEURY S.A.	-18.96%	1.55B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-38.35%	1.21B
METROPOLIS HEALTHCARE LIMITED	+6.91%	1.11B

Medical & Diagnostic Laboratories